Clinical Trial Update: Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating rilotumumab with erlotinib versus erlotinib alone in MET-positive, recurrent stage IV squamous cell lung cancer; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Squamous Cell Lung Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Rilotumumab (rilotumumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: MET Positive, Recurrent Squamous Cell Lung Carcinoma | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2020-03-19